MoonLake Immunotherapeutics (MLTX) said Wednesday that it has screened patients for for three new clinical trials targeting three new indications to assess sonelokimab, an investigational Nanobody aimed at treating inflammatory diseases.
The clinical program for sonelokimab now includes patients with adolescent hidradenitis suppurativa, or HS, palmoplantar pustulosis, or PPP, and axial spondyloarthritis, or axSpA, along with adult patients suffering from HS and active psoriatic arthritis, or PsA.
The new trials include the phase 3 VELA-TEEN trial in adolescent HS, which will evaluate safety and tolerability over 24 weeks in 30 to 40 adolescents; the phase 2 LEDA trial in PPP, assessing the efficacy of a 120mg subcutaneous dose in around 30 patients; and the phase 2 S-OLARIS trial in axSpA, using Positron Emission Tomography and Magnetic Resonance Imaging, or PET/MRI imaging to measure inflammation reduction in 25 patients, the biotechnology company said.
Shares of MoonLake were down 0.4% in recent Wednesday trading.
Price: 50.00, Change: -0.22, Percent Change: -0.43
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.